Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...

That's the top-line finding of the latest financing report from the UK BioIndustry Association (BIA), which reveals that ...

Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition and a groundbreaking surgical nerve treatment for veterans. NEW YORK ...

Underlying this acquisition are three key goals of Innolux: to quickly enter the supply chain of Japanese automakers; to transform from a panel maker to a tier-1 automotive smart cockpit system ...

A trade association that represents cloud providers in the European Union has filed suit over Broadcom Inc.’s acquisition of VMware. The group, CISPE, disclosed the move today. It submitted the ...

The Federal Communications Commission announced on Thursday the approval of a massive, $8 billion acquisition of Paramount Global by Skydance Media.